[1]王润俊.阿托伐他汀改善蛛网膜下腔出血患者的预后分析[J].医学信息,2018,31(14):142-144.[doi:10.3969/j.issn.1006-1959.2018.14.043]
　WANG Run-jun.Analysis of Atorvastatin Improves Prognosis in Patients with Subarachnoid Hemorrhage[J].Journal of Medical Information,2018,31(14):142-144.[doi:10.3969/j.issn.1006-1959.2018.14.043]
点击复制

阿托伐他汀改善蛛网膜下腔出血患者的预后分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
31卷
期数:
2018年14期
页码:
142-144
栏目:
药物与临床
出版日期:
2018-07-15

文章信息/Info

Title:
Analysis of Atorvastatin Improves Prognosis in Patients with Subarachnoid Hemorrhage
文章编号:
1006-1959（2018）14-0142-03
作者:
王润俊
天津市第四中心医院急诊科，天津 300140
Author(s):
WANG Run-jun
Department of Emergency,Tianjin Fourth Central Hospital,Tianjin 300140,China
关键词:
阿托伐他汀; 蛛网膜下腔出血; 血管痉挛
Keywords:
Key words：Atorvastatin; Subarachnoid hemorrhage; Vasospasm
分类号:
R743.35
DOI:
10.3969/j.issn.1006-1959.2018.14.043
文献标志码:
A
摘要:
目的 对阿托伐他汀可降低脑损伤标记物并减少SAH后脑血管痉挛的发生率进行研究。方法 选取2015年1月~12月本院经血管造影明确诊断血管瘤破裂导致的自发性SAH且发病48 h内的患者40例，将其随机分为对照组和阿托伐他汀组,每组20例。对照组给予保护脑神经，预防脑血管痉挛等常规治疗；阿托伐他汀组在对照组常规治疗的基础上给予阿托伐他汀，每周记录谷丙转氨酶，谷草转氨酶以及肌酸激酶评估肝损伤及肌损伤。每天记录脑损伤标记物变化情况。记录血管造影或经颅多普勒测量大脑中动脉血流峰值超过160 m/sec为发生血管痉挛的指标。结果 阿托伐他汀组与对照组肝损伤及肌损伤发生率比较，差异无统计学意义（P＞0.05）。阿托伐他汀组血清中vWF因子平均浓度11.95 ng/ml，低于对照组21.59 ng/ml，差异有统计学意义（P＜0.05）；阿托伐他汀组血清中S100β因子平均浓度50.8 pg/ml，低于对照组190.5 pg/ml，统计学意义显著（P＜0.01）。经颅多普勒大脑中动脉血流峰值阿托伐他汀组（103.11±41.01)m/sec，低于对照组（149.12±48.12）m/sec，统计学意义显著（P＜0.01）。阿托伐他汀组血管痉挛发生率 25.00%，低于对照组60.00%，差异有统计学意义（P＜0.05）。结论 自发性蛛网膜下腔出血患者及早使用阿托伐他汀可明显较少血管痉挛的发生率，并具有良好的安全性及耐受性。阿托伐他汀可降低血清中SHA脑损伤标记物，减少血管痉挛，减轻迟发型缺血性损伤，改善SAH患者预后。
Abstract:
Abstract：Objective To investigate the effect of atorvastatin on reducing the markers of brain injury and reducing the incidence of cerebral vasospasm after SAH.Methods A total of 40 patients with spontaneous SAH and within 48 h onset were diagnosed by angiography in January to December 2015.They were randomly divided into control group and atorvastatin group with 20 cases in each group.The control group was given routine treatment such as protecting the brain nerve and preventing cerebral vasospasm,while the atorvastatin group was given atorvastatin on the basis of the routine treatment in the control group,liver damage and muscle damage were assessed weekly by recording alanine aminotransferase,aspartate aminotransferase,and creatine kinase.Changes in brain damage markers were recorded daily.Recording angiography or transcranial Doppler measurements of peak blood flow in the middle cerebral artery over 160 m/sec is an indicator of vasospasm.Results There was no significant difference in the incidence of liver injury and muscle injury between atorvastatin and control group(P>0.05).The average serum concentration of vWF in atorvastatin group was 11.95 ng/ml,which was significantly lower than that in control group 21.59 ng/ml,the difference was statistically significant (P<0.05),the average concentration of S100β in the serum of atorvastatin group was 50.8 pg/ml,which was lower than that of the control group 190.5 pg/ml,which was statistically significant(P<0.01).Transcranial Doppler middle cerebral artery blood flow peak atorvastatin group(103.11±41.01)m/sec,lower than the control group(149.12±48.12)m/sec,statistically significant(P<0.01).The incidence of vasospasm in the atorvastatin group was 25.00%,which was lower than that in the control group 60.00%,and the difference was statistically significant(P<0.05).Conclusion Early use of atorvastatin in patients with spontaneous subarachnoid hemorrhage can significantly reduce the incidence of vasospasm and has good safety and tolerance.Atorvastatin can reduce serum SHA brain damage markers, reduce vasospasm, reduce delayed ischemic injury, and improve the prognosis of SAH patients.

参考文献/References:

[1]Masato N,Akira M,Naoya M,et al.Suppression of the Rho/Rho-Kinase Pathway and Prevention of Cerebral Vasospasm by Combination Treatment with Statin and Fasudil After Subarachnoid Hemorrhage in Rabbit[J].Translational Stroke Research,2013,4(3):368-374. [2]Sehba FA,Hou J,Pluta RM,et al.The importance of early brain injury after subarachnoid hemorrhage[J].Progress in Neurobiology,2012,97(1):14-37. [3]詹绍萍,刘辉,郁鹏,等.经颅多普勒超声诊断自发性蛛网膜下腔出血后脑血管痉挛[J].中华神经外科疾病研究杂志,2015,14(2):175-176. [4]Kumar G,Shahripour RB,Harrigan MR.Vasospasm on transcranial Doppler is predictive of delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage:a systematic review and meta-analysis[J].Journal of Neurosurgery,2016,124(5):1257-1264. [5]Mrozek S,Dumurgier J,Citerio G,et al.Biomarkers and acute brain injuries: interest and limits[J].Critical Care,2014,18(2):220. [6]杨位霞,毛蕾蕾,袁慧.蛛网膜下腔出血后迟发性脑血管痉挛的机制[J].中华行为医学与脑科学杂志, 2014(11):1048-1050. [7]郝小可,史继新.蛛网膜下腔出血后早期脑损伤机制研究进展[J].医学研究生学报,2015,28(07):767-770.

相似文献/References:

[1]何 丽.三种他汀类药物治疗老年动脉粥样硬化性急性脑梗死合并高血脂效果对比[J].医学信息,2022,35(11):150.[doi:10.3969/j.issn.1006-1959.2022.11.040]
　HE Li.Comparison of Three Statins in the Treatment of Elderly Patients with Atherosclerotic Acute Cerebral Infarction Combined with Hyperlipidemia[J].Journal of Medical Information,2022,35(14):150.[doi:10.3969/j.issn.1006-1959.2022.11.040]
[2]王 毅.阿托伐他汀联合曲美他嗪治疗冠心病的临床效果评价[J].医学信息,2018,31(13):139.[doi:10.3969/j.issn.1006-1959.2018.13.041]
　WANG Yi.Clinical Evaluation of Atto Vastatin Combined with Trimetazidine in the Treatment of Coronary Atherosclerotic Heart Disease[J].Journal of Medical Information,2018,31(14):139.[doi:10.3969/j.issn.1006-1959.2018.13.041]
[3]袁 敏,周袁成.阿托伐他汀联合抗血小板药治疗脑血栓患者的疗效及对 血小板参数的影响[J].医学信息,2018,31(16):123.[doi:10.3969/j.issn.1006-1959.2018.16.038]
　YUAN Min,ZHOU Yuan-cheng.Effect of Atorvastatin Combined with Antiplatelet Drugs on Patients with Cerebral Thrombosis and its Influence on Platelet Parameters[J].Journal of Medical Information,2018,31(14):123.[doi:10.3969/j.issn.1006-1959.2018.16.038]
[4]徐润鸿.血府逐瘀汤联合阿托伐他汀钙治疗急性脑梗死的临床观察[J].医学信息,2019,32(05):165.[doi:10.3969/j.issn.1006-1959.2019.05.054]
　XU Run-hong.Clinical Observation on Treatment of Acute Cerebral Infarction with Xuefu Zhuyu Decoction Combined with Atorvastatin Calcium[J].Journal of Medical Information,2019,32(14):165.[doi:10.3969/j.issn.1006-1959.2019.05.054]
[5]沈有录,卢红涛,刘维军.阿托伐他汀和瑞舒伐他汀对高海拔地区PCI患者血脂、炎症因子和血管内皮功能的影响[J].医学信息,2019,32(06):67.[doi:10.3969/j.issn.1006-1959.2019.06.022]
　SHEN You-lu,LU Hong-tao,LIU Wei-jun.Effects of Atorvastatin and Rosuvastatin on Blood Lipids,Inflammatory Factors and Vascular Endothelial Function in Patients with High Altitude PCI[J].Journal of Medical Information,2019,32(14):67.[doi:10.3969/j.issn.1006-1959.2019.06.022]
[6]陈志萍.阿托伐他汀联合低分子肝素治疗短暂性脑缺血临床疗效[J].医学信息,2019,32(09):153.[doi:10.3969/j.issn.1006-1959.2019.09.051]
　CHEN Zhi-ping.Clinical Efficacy of Atorvastatin Combined with Low Molecular Weight Heparin in the Treatment of Transient Cerebral Ischemia[J].Journal of Medical Information,2019,32(14):153.[doi:10.3969/j.issn.1006-1959.2019.09.051]
[7]高占群,李 霜,刘 杨.苯那普利联合阿托伐他汀治疗冠心病合并2型糖尿病 心功能不全的临床效果[J].医学信息,2019,32(17):135.[doi:10.3969/j.issn.1006-1959.2019.17.044]
　GAO Zhan-qun,LI Shuang,LIU Yang.Clinical Effect of Benazepril Combined with Atorvastatin in the Treatment of Coronary Heart Disease Complicated with Type 2 Diabetes with Cardiac Insufficiency[J].Journal of Medical Information,2019,32(14):135.[doi:10.3969/j.issn.1006-1959.2019.17.044]
[8]安志卫,刘 娜,薛芳芳.阿托伐他汀联合硫酸氢氯吡格雷治疗脑血栓的效果观察[J].医学信息,2019,32(17):148.[doi:10.3969/j.issn.1006-1959.2019.17.049]
　AN Zhi-wei,LIU Na,XUE Fang-fang.Effect of Atorvastatin Combined with Clopidogrel Hydrogen Sulfate on Cerebral Thrombosis[J].Journal of Medical Information,2019,32(14):148.[doi:10.3969/j.issn.1006-1959.2019.17.049]
[9]花国辉.不同剂量阿托伐他汀治疗心梗后无症状心衰的疗效比较[J].医学信息,2020,33(04):153.[doi:10.3969/j.issn.1006-1959.2020.04.050]
　HUA Guo-hui.Comparison of the Effects of Different Doses of Atorvastatin on Asymptomatic Heart Failure After Myocardial Infarction[J].Journal of Medical Information,2020,33(14):153.[doi:10.3969/j.issn.1006-1959.2020.04.050]
[10]赵 虹.阿托伐他汀联合黄连素治疗糖尿病合并脑梗死患者的效果[J].医学信息,2020,33(07):154.[doi:10.3969/j.issn.1006-1959.2020.07.050]
　ZHAO Hong.The Effect of Atorvastatin Combined with Berberine on Diabetic Patients with Cerebral Infarction[J].Journal of Medical Information,2020,33(14):154.[doi:10.3969/j.issn.1006-1959.2020.07.050]

更新日期/Last Update: 2018-07-15